USPTO 2015–2025 USPTO PatentsView US Corporation

10x Genomics, Inc.

USPTO PatentsView assignee record - 373 granted patents across 35 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, 10x ranks #1,132 of 49,997 tracked US assignees by granted-patent volume, with 373 patents across 35 technology areas.

#1,132
of 49,997 US assignees by volume
Top 1%
by Innovation Score (68.9/100)
26.5
avg claims per patent
+329%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1132 · US Corporation #1,132 · 373 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-STRONG · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MID 373 grants
  • TOP-DECILE #1,132/49,997
  • PHOTO-FINISH Huawei Digital Power
  • CPC-FOCUS C12Q · 35 areas
  • INNOV-STRONG 68.9/100
  • CLAIMS-DENSE 26.5 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +329% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Huawei Digital Power Technologies Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around 10x

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows 10x's Innovation Score is 68.9/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where 10x's grants concentrate

10x Genomics, Inc. is a focused PatentsView assignee: 35 CPC subclasses with 75.6% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2024 (82 grants) versus a trough of 4 in 2016. By volume, 10x sits between Mercedes-Benz Group AG and Samsung SDS Co., Ltd..

10x's three-year grant acceleration

From 2019–2021 to 2022–2024, 10x Genomics, Inc. moved from 92 to 173 grants (1.88x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #246. See the growth leaderboard.

Who files at 10x's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows 10x holds 373 patents at rank #1,132, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near 10x

By rank, the assignees closest to #1,132 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in 10x's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for 10x, neither rank-band nor same-CPC leaders (those blocks stay above).

10x's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

69 Top 1% higher than 99% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

020406080100 2016201720182019202020212022202320242025 82
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
10x Genomics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 4 1.1%
2017 7 1.9%
2018 15 4.0%
2019 29 7.8%
2020 41 11.0%
2021 22 5.9%
2022 29 7.8%
2023 62 16.6%
2024 82 22.0%
2025partial year 82 22.0%

Where it ranks

Overall rank by patents

#1,132

of 49,997 tracked assignees

Innovation Score

68.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

10x Genomics, Inc.'s patent record in context - here's where to go next.

  • 10x Genomics, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 75.6% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #1,132 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare 10x Genomics, Inc. against Mercedes-Benz Group AG, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 68.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.